Q-omics provides the consensus-scored IL36A profile across patient tissues and cancer cell-line models. IL36A expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, IL36A is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, IL36A RNA expression shows 9,290 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, HNSC, and THYM as cancer lineages where IL36A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL36A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL36A survival associations across molecular data types. IL36A RNA expression shows survival associations in the most cancer types (18), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL36A RNA expression–survival associations across cancer types. High IL36A expression shows unfavorable associations in CHOL, SCLC, UCEC, UCS and KIRP, but favorable associations in BRCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for IL36A RNA expression.
This table summarizes IL36A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IL36A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL36A shows lower tumor expression in HNSC and KIRC and higher tumor expression in THCA, LUSC, LUAD and PAAD. The HNSC box plot shows higher IL36A RNA expression in normal versus tumor tissue (log2 FC = −4.242, t-test p < 0.001).
This table shows molecular features associated with IL36A in patient tissues and cancer cell lines. In patient samples, IL36A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL36A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
